EXTON, Pa., May 8 /PRNewswire/ -- BioTrends Research Group released highlights from its baseline wave of LaunchTrends(TM): SIMPONI, a four wave syndicated research study that will track uptake of the drug from FDA approval through six months post launch. The research is based on results of a survey of 77 Rheumatologists conducted on-line between May 5th and May 7th.
95% of the Rheumatologists surveyed were aware of SIMPONI and about one-third had been called on by SIMPONI sales representatives. Two-thirds reported a favorable reaction to SIMPONI and 83% reported a high interest in learning more about the product. Among those familiar with SIMPONI, nearly all were aware of the monthly dosing intervals, but overall the respondents were less familiar with the product's indications and dose delivery forms. Compared to the other biologics indicated for RA, 43% identified SIMPONI as the "easiest to administer/easiest for patients to take" while 26% gave Abbott's HUMIRA(R) top billing for ease of use. The respondents reported that close to 40% of their severe RA patients could be considered candidates for SIMPONI and that the majority of SIMPONI patients would be switched from other biologic agents. Market share projections suggest that SIMPONI will primarily draw from other TNF-inhibitors and 38% of the respondents suggest that they will prescribe the product for their RA patients as soon as it is available.
Surveyed Rheumatologists are also highly aware of other late stage biologics awaiting approval such as UCB's CIMZIA(R) and Roche's ACTEMRA(R). 62% of the respondents reported a greater interest in ACTEMRA compared to SIMPONI, primarily due to ACTEMRA's novel mechanism of action. Given a choice between SIMPONI and CIMZIA, the respondents reported a greater interest in SIMPONI by a 3:1 margin.
Centocor Ortho Biotech, Inc. received FDA approval for SIMPONI(R)'/>"/>
|SOURCE BioTrends Research Group, Inc.|
Copyright©2009 PR Newswire.
All rights reserved